Hospital
City & County of San Francisco
City & County of San Francisco was paid $13.11M by Medicaid between Jan 2018 and Nov 2024, across 183 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 78% of everything it billed.
33Billing provider infoCITY & COUNTY OF SAN FRANCISCO
SAN FRANCISCO, CA 94110
SAN FRANCISCO, CA 94110
33aNPI1164609962assigned 01/24/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.11M
24GClaims163,219
24DCodes billed183
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#158 of 410
Median peer was paid$6.90M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ARNOLD, TIMOTHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,823 | $69K | |
| 2019 | 53,664 | $283K | |
| 2020 | 9,762 | $1.08M | |
| 2021 | 9,986 | $1.99M | |
| 2022 | 14,379 | $2.88M | |
| 2023 | 21,733 | $3.80M | |
| 2024incomplete | 15,872 | $3.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 78% | 63,768 | 51,116 | $10.21M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7.5% | 1,951 | 1,408 | $989K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 1,240 | 708 | $399K |
| 90677 | 1.7% | 401 | 401 | $228K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 1,867 | 1,587 | $191K |
| 91320 | 1.1% | 594 | 594 | $151K | |
| 96415 | <1% | 422 | 321 | $87K | |
| 80061 | Lipid panel | <1% | 5,221 | 5,195 | $67K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 828 | 824 | $56K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 361 | 197 | $49K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 76 | 60 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,376 | 6,347 | $37K |
171 more codes
| 80053 | Comprehensive metabolic panel | <1% | 5,099 | $34K |
| 92250 | <1% | 451 | $34K | |
| 90670 | <1% | 565 | $34K | |
| 87536 | <1% | 622 | $33K | |
| 90732 | <1% | 115 | $33K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 991 | $30K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,790 | $29K |
| 91322 | <1% | 111 | $28K | |
| 0760 | <1% | 298 | $21K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 295 | $20K |
| 90750 | <1% | 454 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,064 | $16K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 213 | $15K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 14 | $15K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 42 | $13K |
| 86780 | <1% | 472 | $12K | |
| 0450 | Emergency room services | <1% | 365 | $12K |
| J3490 | Unclassified drugs | <1% | 511 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,119 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 175 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,158 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,142 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 85 | $8K |
| 82043 | <1% | 2,341 | $8K | |
| 82570 | <1% | 2,545 | $8K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 822 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 864 | $7K |
| 85027 | <1% | 2,758 | $7K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 26 | $6K |
| 0270 | <1% | 13 | $5K | |
| G0008 | Administration of influenza virus vaccine | <1% | 143 | $5K |
| 99285 | Emergency room visit (most serious) | <1% | 696 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 517 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 259 | $5K |
| 85610 | <1% | 2,015 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 160 | $4K |
| 99283 | Emergency room visit (moderate) | <1% | 438 | $4K |
| 99284 | Emergency room visit (serious) | <1% | 532 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 41 | $3K |
| 96417 | <1% | 20 | $3K | |
| 84460 | <1% | 933 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 84 | $3K |
| 92002 | <1% | 13 | $3K | |
| 99173 | <1% | 319 | $3K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 277 | $3K |
| 83970 | <1% | 500 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 27 | $3K |
| 87517 | <1% | 344 | $2K | |
| 82728 | <1% | 668 | $2K | |
| 86592 | <1% | 888 | $2K | |
| 82607 | <1% | 425 | $2K | |
| 82105 | <1% | 406 | $2K | |
| 92134 | <1% | 198 | $2K | |
| 80069 | <1% | 798 | $2K | |
| 84466 | <1% | 574 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 471 | $1K |
| 82248 | <1% | 362 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 287 | $1K |
| 84153 | <1% | 382 | $1K | |
| 82803 | <1% | 695 | $1K | |
| 82948 | <1% | 1,843 | $1K | |
| 86141 | <1% | 543 | $1K | |
| 71250 | <1% | 39 | $892.71 | |
| 90651 | <1% | 201 | $790.20 | |
| 81001 | <1% | 1,211 | $699.89 | |
| 83735 | <1% | 1,020 | $689.69 | |
| 80076 | <1% | 1,292 | $659.80 | |
| 36000 | <1% | 525 | $652.74 | |
| 83540 | <1% | 687 | $620.74 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 670 | $610.33 |
| 87088 | <1% | 667 | $559.43 | |
| 71045 | Radiologic examination, chest; single view | <1% | 461 | $404.05 |
| 97802 | <1% | 201 | $364.20 | |
| 83690 | <1% | 546 | $362.63 | |
| 84484 | <1% | 584 | $321.53 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,081 | $314.10 |
| 82565 | <1% | 669 | $288.55 | |
| 87340 | <1% | 222 | $286.40 | |
| 85730 | <1% | 602 | $263.97 | |
| 83880 | <1% | 347 | $241.20 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 137 | $231.87 |
| 84100 | <1% | 657 | $197.83 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 346 | $178.77 |
| 85651 | <1% | 20 | $169.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 27 | $154.00 |
| 86580 | <1% | 59 | $124.50 | |
| 86900 | <1% | 143 | $123.84 | |
| 85652 | <1% | 490 | $116.76 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,272 | $98.44 |
| 87522 | Neg quan hep c or qual rna | <1% | 178 | $97.25 |
| 86901 | <1% | 141 | $94.55 | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 26 | $89.80 |
| 82610 | <1% | 26 | $88.14 | |
| 87430 | <1% | 28 | $75.71 | |
| 83605 | <1% | 214 | $58.57 | |
| 86803 | <1% | 253 | $56.52 | |
| 81002 | <1% | 365 | $56.01 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 405 | $54.70 |
| 90686 | <1% | 1,771 | $54.22 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 98 | $47.55 |
| 90723 | <1% | 397 | $45.00 | |
| 90680 | <1% | 344 | $45.00 | |
| 73630 | <1% | 30 | $43.59 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 41 | $43.16 |
| 84439 | <1% | 369 | $43.13 | |
| 87186 | <1% | 73 | $40.88 | |
| 29581 | <1% | 41 | $38.67 | |
| 87077 | <1% | 82 | $38.23 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 554 | $38.00 |
| 87081 | <1% | 18 | $37.20 | |
| 90715 | <1% | 142 | $36.51 | |
| 83655 | <1% | 158 | $36.40 | |
| 90647 | <1% | 351 | $36.00 | |
| 92015 | Determination of refractive state | <1% | 81 | $35.24 |
| 85018 | <1% | 230 | $33.68 | |
| 0250 | <1% | 102 | $32.45 | |
| 81003 | <1% | 213 | $28.09 | |
| 85008 | <1% | 103 | $27.44 | |
| 86706 | <1% | 173 | $23.72 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 139 | $23.50 |
| 84450 | <1% | 199 | $21.87 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 13 | $17.92 |
| 82550 | <1% | 81 | $17.69 | |
| 85014 | <1% | 83 | $17.01 | |
| 84132 | <1% | 167 | $15.13 | |
| 81025 | <1% | 12 | $14.00 | |
| 86704 | <1% | 72 | $10.83 | |
| 82247 | <1% | 41 | $9.94 | |
| 84165 | <1% | 60 | $9.58 | |
| 70355 | <1% | 26 | $8.58 | |
| 94150 | <1% | 40 | $4.79 | |
| 90662 | <1% | 995 | $0.29 | |
| 90656 | <1% | 321 | $0.08 | |
| 82274 | 0% | 863 | $0.00 | |
| 92133 | 0% | 129 | $0.00 | |
| 90633 | 0% | 290 | $0.00 | |
| 94729 | 0% | 27 | $0.00 | |
| 84550 | 0% | 228 | $0.00 | |
| 90707 | 0% | 154 | $0.00 | |
| 90710 | 0% | 57 | $0.00 | |
| 99152 | 0% | 25 | $0.00 | |
| 90700 | 0% | 126 | $0.00 | |
| 99188 | 0% | 16 | $0.00 | |
| 94726 | 0% | 14 | $0.00 | |
| 86708 | 0% | 12 | $0.00 | |
| 90734 | 0% | 142 | $0.00 | |
| 92083 | 0% | 13 | $0.00 | |
| 85045 | 0% | 29 | $0.00 | |
| 84156 | 0% | 44 | $0.00 | |
| 97803 | 0% | 91 | $0.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 14 | $0.00 |
| 97164 | 0% | 12 | $0.00 | |
| 73030 | 0% | 13 | $0.00 | |
| 86480 | 0% | 32 | $0.00 | |
| 97116 | 0% | 33 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 80 | $0.00 |
| 82040 | 0% | 26 | $0.00 | |
| 94760 | 0% | 132 | $0.00 | |
| 90716 | 0% | 159 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 155 | $0.00 |
| 88142 | 0% | 27 | $0.00 | |
| 86361 | 0% | 120 | $0.00 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 0% | 42 | $0.00 |
| 90696 | 0% | 52 | $0.00 | |
| 90480 | 0% | 22 | $0.00 | |
| 94010 | 0% | 28 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| 73564 | 0% | 28 | $0.00 | |
| 87205 | 0% | 30 | $0.00 | |
| 94200 | 0% | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARNOLD, TIMOTHY (DEPUTY DIRECTOR, PFS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.